Active Biotech
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
ACTI | ST
Overview
Corporate Details
- ISIN(s):
- SE0001137985 (+2 more)
- LEI:
- 549300OJ44CLMRU8YE43
- Country:
- Sweden
- Address:
- Scheelevägen 22, 223 63 Lund
Description
Active Biotech is a biotechnology company that develops pharmaceuticals for specialist indications with high medical need, focusing on oncology and inflammatory eye disorders. The company leverages its knowledge of the immune system to advance its clinical pipeline. Its portfolio includes fully-owned projects such as tasquinimod for hematological cancers, including multiple myeloma and myelofibrosis, and laquinimod, developed as eye drops for non-infectious uveitis. Additionally, the company has licensed projects, including naptumomab, which is being developed in partnership with NeoTX for the treatment of solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2015-11-23 08:31 |
Active Biotech's election committee appointed
|
English | PDF • 142.7 KB | ||
| 2015-11-23 08:31 |
Active Biotechs valberedning utsedd
|
Swedish | PDF • 127.1 KB | ||
| 2015-11-06 09:01 | Swedish | PDF • 231.7 KB | |||
| 2015-11-06 09:01 | English | PDF • 218.4 KB | |||
| 2015-11-06 08:31 |
Active Biotech AB Delårsrapport januari - september 2015
|
Swedish | PDF • 231.7 KB | ||
| 2015-11-06 08:31 |
Active Biotech AB Interim report January - September 2015
|
English | PDF • 218.4 KB | ||
| 2015-10-06 14:01 |
Active Biotechs partner Teva presenterar data för laquinimod mot multipel skler…
|
Swedish | PDF • 106.0 KB | ||
| 2015-10-06 14:01 |
Active Biotech's partner Teva presents data on laquinimod for the treatment of …
|
English | PDF • 126.5 KB | ||
| 2015-09-28 08:31 |
Final results from Active Biotech's 10TASQ10 Phase 3 study of tasquinimod prese…
|
English | PDF • 169.3 KB | ||
| 2015-09-28 08:31 |
Finala resultat från Active Biotechs tasquinimod fas 3-studie 10TASQ10 presente…
|
Swedish | PDF • 130.4 KB | ||
| 2015-08-07 09:29 | Swedish | PDF • 226.5 KB | |||
| 2015-08-07 09:29 | English | PDF • 217.6 KB | |||
| 2015-08-07 08:32 |
Active Biotech AB Delårsrapport januari - juni 2015
|
Swedish | PDF • 226.5 KB | ||
| 2015-08-07 08:32 |
Active Biotech AB Interim report January - June 2015
|
English | PDF • 217.6 KB | ||
| 2015-06-25 14:02 |
Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod…
|
English | PDF • 207.6 KB |
Automate Your Workflow. Get a real-time feed of all Active Biotech filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Active Biotech
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Active Biotech via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Peter Thelin | Other | Other | 164,638,960 | 8,231,948.00 SEK |
| 2024-11-15 | Hans Kolam | Other | Other | 19,800 | 990.00 SEK |
| 2022-09-05 | Aleksandar Danilovski | Other | Buy | 26,672 | 26,672.00 SEK |
| 2022-04-22 | Helen Tuvesson Andersson | Other | Buy | 2,665 | 3,102.86 SEK |
| 2022-04-21 | Helen Tuvesson Andersson | Other | Buy | 37,335 | 41,767.60 SEK |
| 2021-06-17 | Aleksandar Danilovski | Other | Buy | 40,000 | 60,000.00 SEK |
| 2021-06-01 | Michael Shalmi | Other | Buy | 175,000 | 259,437.50 SEK |
| 2021-04-27 | Helen Tuvesson Andersson | Other | Buy | 10,411 | 16,657.60 SEK |
| 2021-04-27 | Helena Eriksson | Other | Buy | 10,000 | 14,460.00 SEK |
| 2021-04-27 | Helen Tuvesson Andersson | Other | Buy | 1,041 | 1,665.60 SEK |
Peer Companies
